SemaThera Inc
www.semathera.comSemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
Read more
SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
Read more
Country
City (Headquarters)
Westmount
Industry
Employees
1-10
Founded
2016
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Operating Officer
Email ****** @****.comPhone (***) ****-****Founder and Chief Scientific Officer
Email ****** @****.comPhone (***) ****-****President , Director and Chief Executive Officer
Email ****** @****.comPhone (***) ****-****
